Genolution

Genolution Capital Expenditures

The Capital Expenditures (CapEx) of Genolution (225220.KQ) as of Nov 19, 2026 is -442.67 M KRW. In the previous year, Capital Expenditures (CapEx) was -12.19 B KRW — a change of -96.37% (higher).

Capital Expenditures

-442.67 MKRW

YoY

-96.37%

Last updated:

Capital Expenditures (CapEx) of Genolution is 2025 -442.67 M KRW. Capital Expenditures (CapEx) of Genolution was 2024 -12.19 B KRW. It decreases by -96.37% higher compared to the previous year.

The Genolution Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-2.92 B KRW
Jan 1, 2019
-3.14 B KRW
Jan 1, 2020
-8.68 B KRW
Jan 1, 2021
-5.13 B KRW
Jan 1, 2022
-22.54 B KRW
Jan 1, 2023
-6.88 B KRW
Jan 1, 2024
-12.19 B KRW
Jan 1, 2025
-442.67 M KRW
The Genolution Capital Expenditures history
YEARCapital ExpendituresYoY
-442.67 MKRW-96.37%
-12.19 BKRW+77.04%
-6.88 BKRW-69.47%
-22.54 BKRW+339.36%
-5.13 BKRW-40.91%
-8.68 BKRW+176.12%
-3.14 BKRW+7.56%
-2.92 BKRW+239.32%
-861.62 MKRW+141.85%
-356.27 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Capital Expenditures (CapEx) of Genolution is -442.67 M KRW in 2025.

Capital Expenditures (CapEx) of Genolution changed from -12.19 B KRW to -442.67 M KRW, representing a -96.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Genolution since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution